- Home
- TJX vs GILD Comparison
TJX vs GILD Comparison
Compare TJX & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TJX | GILD |
|---|---|---|
| Founded | 1962 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.0B | 168.6B |
| IPO Year | 1994 | 2002 |
Fundamental Metrics
Financial Performance| Metric | TJX | GILD |
|---|---|---|
| Price | $157.09 | $133.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 18 |
| Target Price | ★ $169.00 | $148.39 |
| AVG Volume (30 Days) | 4.9M | ★ 5.0M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | 1.23% | ★ 2.55% |
| EPS Growth | 14.32 | ★ 1684.21 |
| EPS | ★ 4.87 | 1.61 |
| Revenue | ★ $29,078,407,000.00 | $24,689,000,000.00 |
| Revenue This Year | $6.75 | $4.68 |
| Revenue Next Year | $5.81 | $6.04 |
| P/E Ratio | ★ $32.64 | $83.56 |
| Revenue Growth | 6.04 | ★ 9.98 |
| 52 Week Low | $119.84 | $105.69 |
| 52 Week High | $165.82 | $157.29 |
Technical Indicators
Market Signals| Indicator | TJX | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 51.20 |
| Support Level | $153.31 | $128.33 |
| Resistance Level | $157.43 | $137.50 |
| Average True Range (ATR) | 3.77 | 3.23 |
| MACD | 1.03 | 0.49 |
| Stochastic Oscillator | 73.36 | 58.95 |
Price Performance
Historical ComparisonAbout TJX TJX Companies Inc. (The)
Founded in 1987, TJX Companies is the world's largest off-price apparel and home fashions retailer, operating more than 5,000 stores across nine countries. In fiscal 2026, the company generated roughly $60 billion in sales. TJX operates through four segments: Marmaxx (61% of sales), HomeGoods (17%), TJX Canada (9%), and TJX international (13%). Its off-price model emphasizes branded merchandise at meaningful discounts, driving high traffic and rapid inventory turnover.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).